Pharmaceutical cost savings of treating obesity with weight loss medications

Obesity Research

Volumn 7, Issue 6, 1999, Pages 523-531

  Greenway, Frank L ^a   Ryan, Donna H ^a   Bray, George A ^a   Rood, Jennifer C ^a   Tucker, Elizabeth W ^a   Smith, Steven R ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Blood pressure; Cholesterol; Cost; Diabetes; Drugs

Indexed keywords

ANOREXIGENIC AGENT; CAFFEINE; EPHEDRINE; FENFLURAMINE; MAZINDOL; PHENTERMINE;

ADOLESCENT; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DRUG COST; ECONOMICS; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MALE; MIDDLE AGED; OBESITY; RISK FACTOR; WEIGHT REDUCTION;

ADOLESCENT; ADULT; APPETITE DEPRESSANTS; CAFFEINE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DRUG COSTS; EPHEDRINE; FEMALE; FENFLURAMINE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; MAZINDOL; MIDDLE AGED; OBESITY; PHENTERMINE; RISK FACTORS; WEIGHT LOSS;

EID: 0033227338     PISSN: 10717323     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1550-8528.1999.tb00709.x     Document Type: Article

References (10)

1. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA. 1994;272:205-11.
2. Anonymous. Trends in ischemic heart disease deaths -United States, 1990-1994. MMWR. 1997;46:146-50.
3. Björvell H, Rössner S. Short communication: a ten-year follow-up of weight change in severely obese subjects treated in a combined behavioural modification programme. Int J Obes. 1992;16:623-5.
4. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes: mellitus. Ann Surg. 1995;222:339-50.
5. Sjostrom CD, Lissner L, Sjostrom L. Relationships between changes in body composition and changes in cardiovascular risk factors: the SOS intervention Study. Obes Res. 1997;5: 519-30.
6. Atkinson RL, Blank RC, Schumacher D, Dhurandhar NV, Ritch DL. Long-term drug treatment of obesity in a private practice setting. Obes Res. 1997;5:578-86.
7. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev. 1995;75:473-86.
8. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Eng J Med. 1997;337:581-8.
9. Edelstein, EG, ed. 96 First Blue Book Databank. New York, NY: Hearst Corporation; 1995.
10. Hunninghake DB. Hyperlipoproteinemias. In: Rakel R, ed. Conn's Current Therapy. Philadelphia, PA: W.B. Saunders Company; 1997;561-5.